ArticleThe oncologist2026

Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial.

Chuanxu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.